Extracellular Aβ42 Oligomers Induce ROCK2 Hyperactivation Through Dual Mediation by RhoA and GzmB: Significance of Moderate ROCK2 Activity in Neural Cells
Open Access
Abstract
Alzheimer’s disease (AD) is characterized by neurite degeneration and neuronal death. Extracellular amyloid-β 1-42 (Aβ42) oligomers (EAO) not only disrupt the homeostasis and function of the extracellular matrix (ECM) but also damage neural cells through direct binding. Previous studies have demonstrated that EAO binding to membrane integrins reduces neuronal motility, adhesion, and neuritogenesis. To identify the key molecular switch(es) responsible for these actin cytoskeleton dysfunction-associated events, this study utilized neuronal and glial cell lines as well as AD model mice to investigate the cascade underlying EAO-induced actin cytoskeleton dysfunction. This study revealed that EAO induce the dual activation of ROCK2 through RhoA and granzyme B (GzmB) mediation, with GzmB-mediated ROCK2 activation constituting a significant component of this process. ROCK2 hyperactivation in response to EAO causes dynamic dysregulation of the actin cytoskeleton, defective neuritogenesis, and ultimately reduced cell survival, leading to disturbances in brain cell populations. However, the excessive inhibition of ROCK2 activity might cause excessive neurite outgrowth, which may disrupt intrinsic neuronal networks or normal neural transmission. Thus, the disruption of ROCK2 activity might lead to impaired neuritogenesis and disturbances in brain cell populations. The findings of this study may provide important insights into AD pathogenesis and feasible therapeutic targets.Keywords
Funding Information
- National Natural Science Foundation of China (31970883)
This publication has 61 references indexed in Scilit:
- Neuroprotective Effects of Catechins by Differentially Affecting the Binding of Beta-amyloid and Its Aggregates to the Target CellsMolecular Neurobiology, 2025
- Mechanistic insights into the potential role of dietary polyphenols and their nanoformulation in the management of Alzheimer’s diseaseBiomedicine & Pharmacotherapy, 2024
- Degradation of amyloid β-peptides catalyzed by nattokinase in vivo and in vitroFood Science and Human Wellness, 2023
- Neuroinflammation in Alzheimer’s Disease: Current Progress in Molecular Signaling and TherapeuticsInflammation, 2022
- Multifaceted neuroprotective effects of (-)-epigallocatechin-3-gallate (EGCG) in Alzheimer’s disease: an overview of pre-clinical studies focused on β-amyloid peptideFood Science and Human Wellness, 2022
- Immune-mediated neurodegenerative trait provoked by multimodal derepression of long-interspersed nuclear element-1iScience, 2022
- Extracellular Amyloid β-protein (1–42) Oligomers Anchor Brain Cells and Make them inert as an Unconventional Integrin-Coupled LigandCellular and Molecular Neurobiology, 2022
- A biophysical perspective of the regulatory mechanisms of ezrin/radixin/moesin proteinsBiophysical Reviews, 2022
- The role of amyloid oligomers in neurodegenerative pathologiesInternational Journal of Biological Macromolecules, 2021
- The Rho-Kinase (ROCK) Inhibitor Y-27632 Protects Against Excitotoxicity-Induced Neuronal Death In Vivo and In VitroNeurotoxicity Research, 2012